TFS
VKTX icon

Thoroughbred Financial Services’s Viking Therapeutics VKTX Stock Holding History

Thoroughbred Financial Services’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,373
Closed -$256K – 730
2024
Q4 		$256K Sell
6,373
-16,051
-72% -$915K 0.02% 586
2024
Q3 		$1.42M Buy
22,424
+3,226
+17% +$189K 0.09% 206
2024
Q2 		$1.02M Buy
19,198
+6,251
+48% +$410K 0.07% 261
2024
Q1 		$1.06M Buy
+12,947
New +$576K 0.1% 192

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Thoroughbred Financial Services's VKTX Position: Q1 2025 in Review

Thoroughbred Financial Services sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 6,373 shares — an estimated $256K sold.

Thoroughbred Financial Services first reported a position in VKTX in Q1 2024 and held it in 4 quarters. The position peaked at $1.42M in Q3 2024. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

  • Thoroughbred Financial Services reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Thoroughbred Financial Services sold 6,373 Viking Therapeutics shares in Q1 2025, an estimated $256K.
  • Thoroughbred Financial Services first reported a position in Viking Therapeutics in Q1 2024 and held it in 4 quarters.
  • Thoroughbred Financial Services's Viking Therapeutics position peaked at $1.42M in Q3 2024.
  • 372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on Thoroughbred Financial Services's 13F filing for Q1 2025, filed 9 May 2025.